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Abstract
Rationale Autoantibodies to central nervous system (CNS)
neuronal surface antigens have been described in association
with autoimmune encephalopathies which prominently fea-
ture psychiatric symptoms in addition to neurological symp-
toms. The potential role of these autoantibodies in primary
psychiatric diseases such as schizophrenia or bipolar affective
disorder is of increasing interest.
Objectives We aimed to review the nature of psychiatric
symptoms associated with neuronal surface autoantibodies,
in the context of autoimmune encephalopathies as well as
primary psychiatric disorders, and to review the mechanisms
of action of these autoantibodies from a psychopharmacolog-
ical perspective.
Results The functional effects of the autoantibodies on their
target antigens are described; their clinical expression is at
least in part mediated by their effects on neuronal receptor
function, primarily at the synapse, usually resulting in receptor
hypofunction. The psychiatric effects of the antibodies are
related to known functions of the receptor target or its com-
plexed proteins, with reference to supportive genetic and phar-
macological evidence where relevant. Evidence for a causal
role of these autoantibodies in primary psychiatric disease is
increasing but remains controversial; relevant methodological
controversies are outlined. Non-receptor-based mechanisms
of autoantibody action, including neuroinflammatory mecha-
nisms, and therapeutic implications are discussed.
Conclusions An analysis of the autoantibodies from a psycho-
pharmacological perspective, as endogenous, bioactive, high-
ly specific, receptor-targeting molecules, provides a valuable
opportunity to understand the neurobiological basis of associ-
ated psychiatric symptoms. Potentially, new treatment strate-
gies will emerge from the improving understanding of
antibody-antigen interaction within the CNS.
Keywords Antibody . Immunoreactivity . Inflammation .
Receptor . NMDA receptor . Potassium channel . GABA
receptor . Limbic system
Introduction
Over the last decade, there has been an increasing recognition
of central nervous system (CNS) syndromes associated with
autoantibodies to CNS cell surface antigens (‘neuronal surface
autoantibodies’ or ‘NSAbs’). The majority of these syn-
dromes feature prominent psychiatric and cognitive symp-
toms, amongst manifold neurological manifestations such as
seizures, movement disorders and autonomic dysfunction and
are best described as ‘autoimmune encephalopathies’.
Recognition of these syndromes and research on the mecha-
nisms of action of their associated, and likely pathogenic,
antibodies has had a huge impact on clinical neurology and
an increasing influence on psychiatry as well.
Given the almost universal occurrence of psychiatric and
cognitive symptoms in these autoimmune encephalopathies,
NSAbs are of considerable interest to researchers studying the
neurobiological bases of psychiatric symptoms. In recent
years, the possibility that NSAbs can cause a ‘purely
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psychiatric’ phenotype has been the object of interest, partly
because of the implication that were this to be the case at least
a subset of what is currently termed primary psychiatric
disease may in fact be NSAb-mediated and potentially
respond to treatment with immunotherapies (Deakin et al.
2014) (Table 1).
Technical developments
The methodology that has facilitated the last decade’s rapid
increase in research has been the development of cell-based
assays (CBAs) using human embryonic kidney (HEK) cells
that have been transfected to express the antigen of interest on
their surface (Rodriguez Cruz et al. 2015). These assays have
a number of advantages over the immunoassays that preceded
CBAs, such as enzyme-linked immunosorbent assay (ELISA)
or radioimmunoassay (RIA). Firstly, the antigenic target is
presented in its native conformation at the cell surface: anti-
bodies which target such proteins are likely to operate in vivo.
Secondly, antibodies that can be demonstrated to target extra-
cellular antigens are likely to be pathogenic (Graus and
Dalmau 2012). Not surprisingly, therefore, the disorders asso-
ciated with NSAbs detectable via CBAs, unlike those associ-
ated with the classical intracellularly directed onconeural an-
tibodies, tend to be immunotherapy-responsive, with some-
times even the most acutely unwell patients making a substan-
tial or even complete recovery following immunotherapy
(Kayser et al. 2013).
The patient’s autoantibodies as pseudo-pharmacological
agents: a new paradigm in psychopharmacology
NSAbs form a unique class in that their clinical expression is
at least in part mediated by their effects on neuronal receptor
function, primarily at the synapse; usually, this results in re-
ceptor hypofunction (see Table 2). Although these effects are
not thought to occur primarily via direct action of the antibody
at the receptor, as is the case with psychotropic drugs, this
general mechanism of action invites an analysis of the anti-
bodies from a pharmacological perspective, as endogenous,
bioactive, highly specific, receptor-targeting molecules. This
concept builds on the established notion of an ‘autoimmune
channelopathy’; but while someNSAbs do target ion channels
(e.g. N-methyl-D-aspartate receptor [NMDAR], α-amino-3-
hydroxy-5-methyl-4-isoxazole propionic acid receptor
[AMPAR], γ-aminobutyric acid receptor [GABAR]), it
should be noted that others are specific for receptor-
associated or regulatory molecules (e.g. contactin-associated
protein-like 2 [CASPR2], leucine-rich glioma inactivated 1
[LGI1], dipeptidyl-peptidase-like protein-6 [DPPX]) or me-
tabotropic cell surface receptors (e.g. dopamine D2 receptor
[D2R], metabotropic glutamate receptor 5 [mGluR5]).
Mutations in many of these proteins have been linked to
neuropsychiatric conditions, strengthening the likelihood of
antibody pathogenicity (Irani et al. 2014).
This review will focus on those CNS-directed NSAbs that
have been associated with clinical syndromes which feature
prominent psychiatric features. Some NSAbs have been more
consistently associated with a particular disease phenotype
than others, although with the passage of time, the number
of conditions in which all NSAbs have been identified con-
tinues to increase (Irani et al. 2014).
The neurological signs and symptoms associated with
NSAbs have been given less focus in this article tomake space
for discussion of psychiatric phenomena; we would direct
readers to the article by Varley and colleagues (Varley et al.
2015) for a more neurologically focussed review.
N-methyl-D-aspartate (NMDA) receptor antibodies
IgG antibodies to the extracellular N-terminal domain of the
NR1 subunit of the NMDAR are associated with NMDAR
antibody encephalitis. First described in 2007 in young wom-
en presenting with neuropsychiatric symptoms in the presence
of an ovarian teratoma (Dalmau et al. 2007), NMDAR en-
cephalitis has a characteristic progression, frequently involv-
ing a viral prodrome followed by two phases of illness. The
early phase includes psychiatric symptoms, cognitive dys-
function and seizures, progressing later to movement disorder,
dysautonomia and coma (Irani et al. 2010a). NMDAR anti-
body encephalitis is increasingly described in older patients,
patients without tumours, men and children (Titulaer et al.
2013).
The nature of psychiatric symptoms associated
with NMDAR NR1-directed antibodies
NMDAR antibodies are of particular interest in psychiatric
research, as approximately 80 % of adults with NMDAR an-
tibody encephalitis initially present with behavioural and psy-
chiatric symptoms (Kayser et al. 2013). Changes in mood,
behaviour or personality are also common early features in
children and adolescents. Symptoms can include anxiety, ag-
itation, bizarre behaviour, catatonia, delusional or paranoid
thoughts and visual or auditory hallucinations, accompanied
bymemory loss (Irani et al. 2010a). It has been recognised that
a minority of individuals only present with one or few symp-
toms, usually psychosis or seizures (Kayser et al. 2013;
Niehusmann et al. 2009). This raises the possibility of a partial
or attenuated syndrome, with a predominance of psychotic
symptoms, accompanied by few or no other clinical charac-
teristics of NMDAR antibody encephalitis.
An observational study by Kayser et al. found 4 % of cases
of NMDAR antibody encephalitis presented with isolated
psychiatric symptoms. This rose to 28 % of a group
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experiencing relapses. Seventy-four percent had delusional
thoughts, 43 % had auditory or visual hallucinations and
57 % had aggressive behaviour. Seventy percent had a mood
component to their presentation including mania, mood labil-
ity, impulsivity, disinhibition and depressive or nonspecific
mood changes (Kayser et al. 2013). The clinical picture has
broadened further with a recent study finding 2 % of cases of
post-partum psychosis had NMDAR antibodies (Bergink
et al. 2015).
Effects of immunotherapy
Most patients with a diagnosis of NMDAR antibody enceph-
alitis experience a substantial improvement in their symptoms
when treated with immunotherapy (first line: steroids, intrave-
nous immunoglobulin (IVIg), plasma exchange; second line:
rituximab, cyclophosphamide) and/or tumour removal
(Titulaer et al. 2013), with early treatment a predictor of a
good outcome (Kayser et al. 2013). Nevertheless, a majority
of patients experience persistent subjective cognitive deficits
or have deficits on cognitive testing includingmemory impair-
ment and executive dysfunction (Finke et al. 2012). Memory
deficits correlate with hippocampal damage on MR imaging,
the extent of which is predicted by disease severity and dura-
tion, highlighting the importance of early diagnosis and ap-
propriate treatment (Finke et al. 2012, 2015).
Potential mechanisms underlying the psychiatric effects
of NMDAR N1 antibodies
Of all NSAbs, the mechanisms underlying the effects of
NMDAR NR1 antibodies have been most extensively inves-
tigated and mimic many of the mechanisms established orig-
inally in the study of pathogenic antibodies directed against
the acetylcholine receptor in myasthenia gravis, the prototyp-
ical antibody-mediated neurological disorder. Although the
epitope is located within the N-terminus that also contains
the glycine binding site, it has been demonstrated that
NMDAR antibodies do not have a direct action at the receptor
(Moscato et al. 2014). Rather they cause a reversible, time-
and dose-dependent internalisation of cell membrane-bound
NMDARs with a subsequent decrease in synaptic and
extrasynaptic receptor density and a reduction in NMDAR-
mediated currents and synaptic plasticity (Fig. 1 and Table 2).
Glutamate dysfunction, in particular NMDAR hypofunction,
is thought to be central to the pathophysiology of schizophrenia
(Howes et al. 2015). NMDAR antagonists such as phencyclidine
(PCP) and ketamine are able to induce psychotic and cognitive
symptoms resembling those seen in psychotic disorders (Javitt
2007) and are similar to those described in NMDAR antibody
encephalitis. Furthermore, PCP can stimulate agitation and dis-
sociative states including reduced responsiveness with catatonic
features (Javitt and Zukin 1991), well-described in NMDARTa
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antibody encephalitis. NMDAR antibodies also cause an in-
crease in extracellular glutamate (Manto et al. 2010), an effect
directly comparable to that of the non-competitive NMDAR an-
tagonist ketamine (Liu and Moghaddam 1995). The psychotic
symptoms associated with ketamine use are directly linked to
cortical glutamate levels (Stone et al. 2012), suggesting that this
could also be a mechanism by which NMDAR antibodies cause
psychosis.
Partial NR1 knockout mice display schizophrenia-related
behaviours, including cognitive impairment (Belforte et al.
2010). Multiple genes associated with schizophrenia are relat-
ed to the NMDAR and associated synaptic proteins (Hall et al.
2015; Kirov et al. 2012; Timms et al. 2013). Post-mortem data
provide evidence for abnormalities in the NMDAR in patients
with schizophrenia (Rubio et al. 2012). There is also in vivo
evidence for reduced NMDAR in the hippocampus of unmed-
icated patients with schizophrenia (Rubio et al. 2012;
Pilowsky et al. 2006). Furthermore, there is some limited ev-
idence that drugs modulating the NMDAR are effective in
schizophrenia (Stone 2011).
Planaguma and colleagues developed an animal model of
NMDAR encephalitis in which patient CSF IgG was admin-
istered to mice via intraventricular infusion over 14 days. The
mice had memory impairments, anhedonia and depressive
behaviour, but there were no effects on anxiety or locomotor
activity (Planaguma et al. 2015). From the neuropsychiatric
perspective, while this model shows clear in vivo effects of
NMDAR antibodies, it does not provide a good fit with the
phenomenology of NMDAR antibody encephalitis, a condi-
tion frequently characterised by agitation, anxiety and affec-
tive lability or even mood elevation. Further, despite psycho-
sis being the most common psychiatric feature, the authors did
not assess effects on paradigms used in animal models of
psychosis. Given the absence of any clear epileptic seizures,
autonomic dysfunction or movement disorders in the mice, it
is also unclear how valid a model this is of NMDAR antibody
encephalitis more broadly.
Other NMDAR antibodies
NMDAR NR2 antibodies, as detected using ELISA, have
been implicated in neuropsychiatric systemic lupus erythema-
tosus (SLE) (Lauvsnes and Omdal 2012), where they have
also been associated with a reduction in hippocampal volume
(Lauvsnes et al. 2014). No published work to date has ad-
dressed whether there is overlap between the antibodies in this
population and with the NR1 antibodies implicated in
NMDAR encephalitis, but the detection methods are suffi-
ciently different to suggest no overlap exists.
More recently, neuropsychiatric presentations have also
been associated with IgA and IgM NMDAR antibodies.
NMDAR IgA and IgM antibodies have been found in patients
with progressive cognitive dysfunction and dementia (Pruss et
al. 2012a; Doss et al. 2014), and IgM antibodies have been
identified in cases of bipolar affective disorder and psychosis
(Choe et al. 2013; Hammer et al. 2014). These studies also
provide growing evidence for their pathogenicity in vitro, but
this is not as robust as for the IgG subtype. However, their
presence in the CSF of some patients may suggest that they
have pathogenic potential (Doss et al. 2014).
Voltage-gated potassium channel (VGKC) complex
antibodies
Initially described in association with peripheral nerve hyper-
excitability, antibodies that immunoprecipitated the alpha-
dentrotoxin-sensitive VGKC alpha subunits were soon
(Liguori et al. 2001) recognised in Morvan’s syndrome, a con-
dition featuring both peripheral nerve and neuropsychiatric
C1q
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2. Complement 
ﬁxaon
PRESYNAPTIC
POST-
SYNAPTIC
VGKC or 
AMPAR C9 
neo 
and 
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Fig. 1 Potential mechanisms of
action of NSAbs. Specific NSAbs
represented here are examples
only and multiple mechanisms
may be shared by different
NSAbs. Note that NSAbs are
likely to have relevant
downstream effects on
intraneuronal signalling,
compensatory changes in the
expression of other surface
proteins and effects on larger-
scale neuronal network function.
Figure reproduced with kind
permission from Varley et al.
(Varley et al. 2015)
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symptoms including anxiety, obsessional behaviour, sleep-
wake disruption and psychosis (Irani et al. 2012). Limbic en-
cephalopathy in association with VGKC complex antibodies
was first described in 2001 (Buckley et al. 2001). Memory
deficits, disorientation and medial temporal lobe seizures pre-
dominate, although psychiatric symptoms are often present and
may occasionally be the presenting feature (Thieben et al.
2004). Psychiatric symptoms include, in order of decreasing
frequency, personality change, depression, anxiety, visual hal-
lucinations, spells and delusions (Somers et al. 2011). Sleep
abnormalities are common (Cornelius et al. 2011).
Some patients with VGKC complex antibody-associated
encephalopathies present initially to psychiatric services, al-
though this proportion is smaller than in NMDAR encephalitis.
Patients with VGKC complex antibodies tend to be older than
those with NMDAR antibodies (Paterson et al. 2014). In addi-
tion to the prominence of cognitive and psychiatric symptoms,
a number of cases have now been described in which VGKC
complex antibodies have been associated with a predominantly
psychiatric phenotype, usually comprising a schizophreniform
or more polymorphic psychosis with varying degrees of cog-
nitive deficit (Somers et al. 2011; Zandi et al. 2011;
Parthasarathi et al. 2006; Tang et al. 2015), although it is un-
clear whether this includes cases in which the antibodies are
causally relevant (see below) (Paterson et al. 2014).
Antibodies to VGKC-‘complexed’ proteins
VGKC complex antibodies were initially detected using a ra-
dioimmunoassay which detects immunoprecipitation of alpha-
dendrotoxin-labelled VGKCs from mammalian brain tissue.
Subsequent inductive biochemical experiments have demon-
strated that some VGKC antibodies are not usually directed
against the VGKCs themselves but against one or more of three
proteins strongly complexed with the VGKC in mammalian
brain: LGI1, CASPR2 and contactin-2 (Irani et al. 2010b).
LGI1 antibodies are more frequently associated with epi-
lepsy and encephalopathy syndromes, while CASPR2 anti-
bodies are more commonly associated with disorders of pe-
ripheral nerve hyperexcitability including Morvan’s syn-
drome. This is consistent with the CNS-predominant expres-
sion of LGI1, whereas CASPR2 is expressed densely at
juxtaparanodes in the CNS and PNS. A highly distinctive
seizure semiology described as faciobrachial dystonic seizures
(FBDS) precedes the development of frank encephalopathy in
a proportion of cases with LGI1 antibodies (Irani et al. 2011).
Both LGI1 and CASPR2 antibody-associated encephalopa-
thies respond well to prompt immunotherapy, although resid-
ual amnestic deficits are common (Butler et al. 2014) and may
occur as a function of time to treatment in LGI1 antibody
encephalopathy (Irani et al. 2013).
Functionally, LGI1 antibodies specifically block the binding
of LGI1 toADAM22/ADAM23with a corresponding decrease
in synaptic AMPAR density (Ohkawa et al. 2013). However,
given the clear phenotypic differences between LGI1 antibody
encephalitis and AMPAR antibody encephalitis (see below), it
is likely that LGI1 antibodies find clinical expression through
mechanisms additional to a reduction of synaptic AMPAR
numbers or function. In this regard, there is evidence from a
single study that LGI1 antibodies may also act via direct inter-
ference with the VGKCs, potentiating hippocampal mossy fi-
bre to CA3 pyramidal cell transmission (Lalic et al. 2011). This
is also supported by the frequent detection of LGI1 antibodies
using the VGKC complex radioimmunoassay.
Intriguingly, mutations in the LGI1 gene in humans are
associated with lateral temporal lobe epilepsy syndromes with
prominent auditory and sometimes visual and even psychic
auras (Striano et al. 2011). The mutations are not however
associated with increased rates of primary psychiatric illness.
Mutations in the gene encoding CASPR2, CNTNAP2, are
associated with schizophrenia, epilepsy and autism (Alarcon
et al. 2008; Friedman et al. 2008).
AMPA receptor antibodies
Antibodies to the GluR1 and GluR2 AMPAR subunits have
been associated with limbic encephalitis characterised by
short-term memory deficits, emotional and behavioural
changes and seizures. Initially described in ten patients from
a series of 109 cases of limbic encephalitis, the majority of
cases were older women and seven had tumours (of the lung,
breast or thymus). Nine patients responded to immunotherapy
or oncological therapy. However, neurological relapses with-
out tumour recurrence were frequent (Lai et al. 2009).
More recently, two studies retrospectively tested for
AMPAR antibodies in samples from patients with more varied
clinical presentations (Hoftberger et al. 2015; Dogan
Onugoren et al. 2014). One included 4,819 samples from pa-
tients with a wide range of neuropsychiatric presentations.
Three were positive for GluR2 AMPAR antibodies, with one
having an ovarian tumour. All presented with memory defi-
cits, and two had psychiatric symptoms, including anxiety and
mood symptoms (Dogan Onugoren et al. 2014). The other
study contained 10,573 patients presenting with suspected
encephalitis or paraneoplastic syndromes and found 22 pa-
tients positive for AMPAR antibodies. Six had psychotic
symptoms as part of their presentation. One of these pa-
tients presented with a week of an isolated psychotic ill-
ness, before developing neuroleptic malignant syndrome in
response to antipsychotic medication. Most patients had a
tumour and a good or partial response to immunotherapy
or surgery (Hoftberger et al. 2015).
Case studies further highlight the potential for presenta-
tions with almost exclusively psychiatric symptoms. Two de-
scribe patients presenting with acute behavioural changes
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(agitation, confusion and aggression). One had an associated
dysphasia, and the other had a past history of thymoma. Both
showed a poor response to neuroleptics but a good response to
corticosteroids (Graus et al. 2010). The third describes an
older woman presenting with headache, confusion, hallucina-
tions and paranoia. Her symptoms responded to IVIg therapy
but relapsed (Elamin et al. 2015). These case studies raise the
possibility of a predominantly psychiatric presentation with
limited neurological associations, potentially amenable to
immunomodulation (Graus et al. 2010). Other case studies
describe psychiatric symptoms but as part of a more varied
clinical presentation (Bataller et al. 2010; Wei et al. 2013).
Potential mechanisms of AMPAR antibodies
AMPAR antibodies reversibly reduce the total surface amount
and synaptic localization of GLuR1 and GLuR2 containing
AMPARs by internalisation and degradation of AMPAR clus-
ters (Lai et al. 2009; Peng et al. 2015), with an accompanying
reduction in AMPAR-medicated currents (Gleichman et al.
2014; Peng et al. 2015). Together, these changes appear to
result in a compensatory decrease of inhibitory synaptic trans-
mission and increase in intrinsic excitability of neurons.
AMPARs are ionotropic glutamate receptors involved in
both fast glutamatergic neurotransmission and activation of
NMDARs (Malinow andMalenka 2002). By the nature of their
interaction with NMDARs, it is possible that changes in the
activity of these receptors could induce psychotic symptoms.
They are important in synaptic plasticity, learning and memory
(Malinow and Malenka 2002; Kessels and Malinow 2009;
Keifer and Zheng 2010). Post-mortem studies have found al-
terations in the expression and binding sites of AMPAR in
schizophrenia (Rubio et al. 2012; Meador-Woodruff and
Healy 2000) and mood disorders (Freudenberg et al. 2015;
Alt et al. 2006; Gibbons et al. 2012). Mice lacking the
AMPA GLuR1 receptor display schizophrenia-related behav-
iours (Wiedholz et al. 2008) and depressive-related behaviours
(Chourbaji et al. 2008).
AMPAR potentiating drugs have moderate effect on cog-
nitive symptoms in schizophrenia when co-administered with
antipsychotics, but this is the subject of an ongoing research
(Goff et al. 2001; Menniti et al. 2013). There is also evidence
for an antidepressant effect in animal studies, and clinical trials
are in progress (Freudenberg et al. 2015; Alt et al. 2006; Li
et al. 2001).
GABA receptor antibodies
Antibodies to the GABAB receptor have been described in
limbic encephalitis with seizures and associate with an under-
lying lung or neuroendocrine tumour in approximately half of
patients (Hoftberger et al. 2013). The psychiatric features
described as part of the limbic encephalitis (memory loss, con-
fusion, personality change; psychosis occurring in about a third
(Lancaster et al. 2010)) do not differentiate GABABR enceph-
alitis from other NSAb-associated limbic encephalitides.
GABAAR antibodies targeting isoforms containing α1 or
β3 subunits were described in a series of 18 patients, of whom
six had high titre antibodies which were also detectable in
CSF and presented with severe encephalitis and refractory
seizures. The other subjects, with lower titre antibodies detect-
able in serum only, had a more varied clinical presentation and
often had other serum NSAbs (Petit-Pedrol et al. 2014).
Pettingill and colleagues retrospectively identified GABAAR
antibodies specific for the α1 and γ2 subunits in the sera of 40
of 2,046 patients with varied clinical features whose sera were
negative for other NSAbs (Pettingill et al. 2015). Surprisingly,
around half were IgM antibodies but all bound to live neurons.
This approach has resulted in more varied clinical associa-
tions: psychiatric features were present in 5/15 for whom clin-
ical data were available—these included patients with
established psychiatric diagnoses of schizophrenia,
obsessive-compulsive disorder and ‘catatonia of unknown or-
igin’. This last patient was a 17-year-old male who presented
with anxiety, obsessionality and psychosis symptoms before
developing catatonic motor symptoms which improved with
plasma exchange on two separate occasions.
Potential mechanisms of GABAR antibody effects
GABAR hypofunction is a plausible mechanism for the gen-
eration of psychiatric symptoms in these patients.
Polymorphisms in genes encoding GABARs have been asso-
ciated with multiple psychiatric presentations, including au-
tism, anxiety disorders and psychotic disorders. Reduced
GABAAR availability is associated with psychotic disorders
(Frankle et al. 2015) and clinical risk for such disorders (Kang
et al. 2014).
Dopamine receptor antibodies
Reactivity to D2R was described using ELISA and western
blot with antibodies purified from individuals with basal gan-
glia disorders associated with streptococcal infection, includ-
ing Sydenham’s chorea and paediatric autoimmune neuropsy-
chiatric disorders associated with streptococcal infections
(PANDAS), and as such the psychiatric associations
encompassed anxiety, obsessions, compulsions and tics
(Brimberg et al. 2012). In contrast to most of the NSAbs
described here, these antibodies appeared to potentiate rather
than antagonise their target receptor-based signalling (Cox
et al. 2013; Brimberg et al. 2012). This is in keeping with
the considerable evidence for striatal hyperdopaminergia in
tic disorders and obsessive-compulsive disorder (OCD)
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(Denys et al. 2013). Increased levels of dopamine D1 receptor
antibodies have since been reported in OCD and Tourette
syndrome (Cox et al. 2015), but as these were detected with
methods that offer less natively conformational epitopes than
CBAs their pathogenicity is unclear.
Studies using CBAs confirmed reactivity with cell surface
D2Rs (providing stronger evidence of pathogenicity) in
Sydenham’s chorea but not in PANDAS. These NSAbs were
also found in Tourette syndrome and paediatric basal ganglia
encephalitis with prominent psychiatric symptoms (also
termed paediatric dyskinetic encephalitis lethargica) and
first-onset paediatric psychosis (Pathmanandavel et al. 2015;
Dale et al. 2012), expanding the psychiatric phenotype to in-
clude psychosis. Whether these D2R antibodies stimulate the
D2R has not yet been demonstrated, but this would be con-
sistent with the now considerable evidence for dopaminergic
overactivity in psychosis (Howes et al. 2012). A large study of
adults with schizophrenia experiencing an acute psychotic ep-
isode however failed to find D2R antibody positivity in this
group (Muller et al. 2014), although notably the CBA meth-
odology differed considerably from the previous study.
Other antigen targets
Glycine receptor and voltage-gated calcium channel (VGCC)
antibodies have been consistently associated with characteris-
tic neurological symptoms but are rarely associated with psy-
chiatric symptoms. This is somewhat surprising in the case of
VGCC antibodies given the compelling evidence for the role
of calcium ion channel gene defects in multiple psychiatric
disorders (Cross-Disorder Group of the Psychiatric
Genomics, C 2013). The neuroanatomical specificities of the
NSAbs or their cognate antigens may be relevant here, with
glycine receptor antibodies predominantly affecting brainstem
structures and the described CNS specificities of VGCC anti-
bodies to date appearing to favour the cerebellum (Burk et al.
2010; Fukuda et al. 2003).
To date, fewer than 30 patients have been described with an
encephalopathy syndrome associated antibodies to DPPX, a
regulatory subunit of A-type (rapidly inactivating) potassium
channels (Boronat et al. 2013; Tobin et al. 2014). Although
initially described in connection with prominent gastrointesti-
nal symptoms, presumably due to the high levels of DPPX in
the myenteric plexus, the disorder can have CNS-only mani-
festations. From a neuropsychiatric viewpoint, in the largest
series described to date, 80 % had amnesia, 40% delirium and
20 % had each of psychosis and depression (Tobin et al.
2014).
Four patients have been described with limbic encephalitis
and antibodies to mGluR5. Psychiatric symptoms including
psychosis and affective and personality changes were promi-
nent; three had Hodgkin lymphoma (Lancaster et al. 2011;
Pruss et al. 2014; Mat et al. 2013). The effect of the NSAbs
onmGluR5, which is thought to regulate NMDAR-dependent
signalling, is unknown. Notably, dysfunction of mGluR5 is
implicated in the pathogenesis of glutamate dysfunction in
psychiatric disorders including schizophrenia (Matosin et al.
2015). Compounds that act on the mGLuR are being devel-
oped for the treatment of schizophrenia (Patil et al. 2007), but
it is currently unclear if they are effective.
Non-receptor-based effects
While this review has emphasised the theoretical utility of
viewing NSAb function from a pharmacological perspective,
it is important to note that NSAbs have other effects consistent
with their role as immune effector molecules. In LGI1
antibody-mediated encephalitis but not in NMDAR antibody
encephalitis, for example, there is consistent evidence of com-
plement deposition and associated cell death in patient brain
tissue (Bien et al. 2012).
Pathological studies of NMDAR antibody encephalitis
have demonstrated the presence of activated microglia
(Dalmau et al. 2008). Consistent with this, microglial activa-
tion in a man with NMDAR antibody encephalitis has been
demonstrated in vivo using a TSPO-specific PET ligand; the
degree of microglial activation was found to correlate with
clinical severity and antibody titre (Jensen et al. 2015).
Surprisingly, little work has focussed on the role of inflam-
matory mediators such as cytokines and chemokines in
NSAb-associated CNS disease. One study found evidence of
involvement of the Th-17 pathway (Ulusoy et al. 2012), but
this requires replication and further work to elucidate potential
differences in the inflammatory milieu associated with differ-
ent NSAbs. Given the increasing recognition of the role of
inflammation in primary psychiatric disease, studies of this
kind may offer further insights of the pathogenesis of
antibody-mediated psychiatric symptoms across diagnoses.
The importance of the inflammatory effects of NSAbs in
human disease is unclear and is likely to vary according to the
antigen target, immunoglobulin subtype (e.g. IgG4 antibodies
are thought to act mainly through effects on receptor function
(Huijbers et al. 2015)) and disease stage (for example, inflam-
matory effects may contribute to the residual symptomatology
seen in many post-encephalitic patients, as is likely the case in
hippocampal atrophy following LGI1-antibody encephalopa-
thy (Malter et al. 2014).
Evidence for NSAbs in primary psychiatric disease
This review has detailed how NSAbs can cause psychiatric
symptoms as part of a wider constellation of neurological
symptoms in autoimmune encephalopathies. There is also
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now an understandable vogue to similarly study the neuropsy-
chiatric features of neurological disorders such as epilepsy or
dementia, in which NSAbs have been variably linked with the
presence of psychiatric symptoms, in particular psychosis
(Doss et al. 2014; Busse et al. 2014; Ekizoglu et al. 2014).
One of the most controversial areas of psychiatric research
today concerns the further question of whether NSAbs have
a causal role in psychiatric disorders such as schizophrenia,
affective disorders or autistic spectrum disorders.
Controversies and limitations of current evidence
Despite a considerable research effort, there has been relative-
ly disappointing progress in the identification of novel biolog-
ical treatments for psychiatric disorders. The possibility of
NSAb-mediated psychiatric disease has been met with great
enthusiasm probably because it raises the prospect of an en-
tirely new class of therapy for at least a subset of these highly
disabling illnesses.
There are presently a number of case studies and series,
albeit uncontrolled, demonstrating immunotherapy-
responsive psychiatric presentations associated with NSAbs
(Table 1). The main controversies remaining are whether se-
rum antibodies alone are sufficient to diagnose an antibody-
mediated CNS disease and whether these cases are a rarity or
whether they might account for a significant proportion of
individuals with a given psychiatric diagnosis. Evidence for
either possibility is inconsistent and the literature has been
beset with debate around the most appropriate methodologies
for establishing the presence of causally relevant antibodies.
Most research has focussed on schizophrenia and psycho-
sis, probably because of the frequency with which psychosis
features in autoimmune encephalopathies but also because of
(a) the theoretically appealing links between neurotransmitter
receptors as NSAb targets and the suggested role of these
neurotransmitters (e.g. NMDAR, AMPAR, D2R) in the path-
ogenesis of psychotic disorders, (b) epidemiological evidence
highlighting a strikingly increased risk of psychosis in people
with autoimmune disorders and vice versa (Benros et al. 2011,
2014) and (c) powerful genome-wide evidence of the central-
ity of immune-related genes in psychosis (Schizophrenia
Working Group of the Psychiatric Genomics, C 2014).
Taking NMDAR antibodies in psychotic disorders as the
most studied example, some studies using live, non-
permeabilised CBAs have demonstrated increased rates of
NMDAR antibodies in psychotic disorders (Pathmanandavel
et al. 2015; Zandi et al. 2011). Studies employing fixed and
permeabilised CBAs however have broadly found similar
prevalences of NMDAR antibodies in patients and in controls
(Dahm et al. 2014; Hammer et al. 2014), while studies using
multiple assays have failed to find any NMDAR antibodies in
psychotic patients (Masdeu et al. 2012). Notably, as well as
the inter-assay variability, patients in each of these studies
differed markedly in terms of chronicity and acuity of illness
(see (Pollak et al. 2014)).
There are a number of areas of controversy regarding test-
ing for NSAbs, particularly in populations with ‘atypical’ pre-
sentations—that is, whose symptoms differ from the canonical
encephalopathy syndromes described above. (1) The necessi-
ty of testing CSF as opposed to serum alone is disputed.
Intrathecal antibody synthesis appears to be common for some
NSAbs but not others (e.g. common in NMDAR antibody
encephalitis but not LGI1 antibody encephalitis (Malter et al.
2013))—but whether antibodies are detectable in CSF may
depend on disease stage and the specificities of the assay used
such as the dilutions at which serum and CSF are tested (see
Irani et al. for further detail (Irani et al. 2014)). (2) The deci-
sion to use fixed as opposed to live CBAs may impact the
outcome of prevalence studies since fixation of cells modifies
the antigen and permeabilises the cell membrane. The latter
may expose intracellular antigens and therefore potentially
detect causally irrelevant antibodies. (3) The association be-
tween psychiatric disorders and NSAbs may depend on the
seropositivity threshold employed in the CBA, with one meta-
analysis indicating higher odds of NMDAR antibody seropos-
itivity in psychotic and affective disorders at lower titres
(Pearlman and Najjar 2014). Most CBAs ascertain titre by
performing serial dilutions and ascertaining the lowest dilu-
tion at which immunofluorescence is detected. More finely
grained quantitative CBA results are possible using
fluorescence-activated cell sorting (Amatoury et al. 2013),
but so far, this is limited to a small number of laboratories
and the sensitivity of the method has in one study been shown
to be inferior to microscopy (Ramberger et al. 2015). (4) Since
NMDAR antibody encephalitis is associated with IgG anti-
bodies, it had been assumed that only these antibodies had
functional effects and hence could cause disease. However,
as mentioned in the section on NMDAR antibodies, there is
now increasing evidence that antibodies of IgA and IgM sub-
classes may have a pathogenic role in psychiatric and neuro-
degenerative disorders (Pruss et al. 2012a; Doss et al. 2014;
Choe et al. 2013; Hammer et al. 2014). (5) Finally, the neces-
sity of confirming a CBA result with other techniques to dem-
onstrate immunoreactivity, such as immunohistochemistry or
assessment of antibody binding to cultured neurons, is also
debated (Zandi et al. 2015; Kayser 2015).
Future directions
It is clear at this stage that studies purporting to show an
increased prevalence of a given NSAb in a particular psychi-
atric patient group cannot in isolation establish that these an-
tibodies have any pathogenic role. Although the recognised
frequencies of these antibodies in a variety of disease and
healthy populations (Dahm et al. 2014) suggest that thorough
epidemiology should be revisited with detailed clinical
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correlations. One potentially powerful argument for the causal
relevance of NSAbs in individuals with a psychiatric diagno-
sis comes from case reports and series demonstrating psychi-
atric improvement following immunotherapy in patients with
NSAbs and a primary psychiatric diagnosis (Zandi et al. 2011,
2014)—although this could relate to an antibody-independent
immunological process for which the antibody is a non-
causative biomarker. Randomised controlled trials of immu-
notherapy in these patient groups are necessary to establish
efficacy before standard psychiatric treatment is substantially
changed, however.
Another argument for pathogenicity of NSAbs in psychi-
atric groups comes from increasing evidence of in vivo and
in vitro functional effects of antibodies from patients with a
primary psychiatric disorder (Choe et al. 2013; Hammer et al.
2014). That is, if the effects on receptor number, function and
cell signalling, or indeed animal behaviour, resemble those
seen with antibodies from patients with encephalitis
(Table 2), then the case for pathogenicity of these NSAbs
would appear at least equal to that in cases of encephalitis.
However, if the antibodies are derived from the serum, it may
be that the CNS is never accessed by these IgG species.
An alternative question concerns whether, when found in
individuals with psychiatric disorders, NSAbs are a secondary
phenomenon, emerging as part of an immune response to
whichever pathogenetic process is driving the disease process.
Importantly, this does not exclude the possibility that NSAbs,
even if secondary, can influence clinical phenotype and/or
disease course. One way to distinguish this possibility from
a more straightforward causal role would be if NSAbs were
not detected in serum samples from individuals at high risk for
psychiatric illness (e.g. the ‘at-risk mental state’ for psychotic
disorders) but became detectable after the onset of clinical
disease. Alternatively, NSAbs may have prognostic signifi-
cance in psychiatric disorders, akin to the prognostic role of
other autoantibodies in many disorders throughout medicine.
Much work remains to be done to elucidate the conditions
required for NSAbs to be produced and to cause CNS dys-
function, with potential relevance for psychiatry. Some au-
thors have highlighted the importance of blood–brain barrier
(BBB) dysfunction in determining whether peripheral anti-
bodies can reach the CNS and exert pathogenic functional
effects (Hammer et al. 2014; Huerta et al. 2006; Levin et al.
2010). With increasing recognition that the majority of NSAb
seropositivity is not associated primarily with malignancy,
attention has also turned to infection as a potential antecedent
of pathogenic NSAb formation; possible mechanisms include
nonspecific adaptive immune response to neuronal damage
and molecular mimicry (Bogdanos et al. 2013). Particular
links between the formation of glutamate receptor antibodies
and influenza (Hammer et al. 2014), HSV-1 (Pruss et al.
2012b; Armangue et al. 2014), EBV (Xu et al. 2011) and other
viral (Koustova et al. 2001) infections have been
demonstrated. Interestingly, serological evidence of viral or
other infections has also been linked with risk for psychosis
(Wang et al. 2011; Amminger et al. 2007; Yolken and Torrey
2008) or with particular phenotypes within psychosis popula-
tions including cognitive impairment (Shirts et al. 2008) and
neuroimaging abnormalities (Schretlen et al. 2010; Prasad
et al. 2011); whether NSAbs might mediate this relationship
in a subset of cases has not been explored.
Therapeutic considerations
NSAbs are immune effector molecules which target specific
CNS receptor targets or other antigenic targets which directly
impact upon receptor function. Therapeutically, two broad
approaches can therefore be considered: immunological and
receptor-based therapies. Precedent for this can be found in
the treatment of myasthenia gravis, in which most patients
have antibodies to cell surface nicotinic acetylcholine recep-
tors. Therapy for the disease is usually a combination of im-
munotherapy targeting the antibodies and cholinergic therapy
aimed at restoring the cholinergic balance at the neuromuscu-
lar junction. Similarly, targeted therapies for NSAb-mediated
disease may similarly be employed simultaneously on two
fronts.
Current immunotherapy for NSAb-mediated CNS disease
can be divided into first-line and second-line therapies. First-
line therapies include oral or intravenous steroids for nonspe-
cific immunosuppression, plasma exchange and intravenous
immunoglobulins. Second-line therapies include cyclophos-
phamide, mycophenolate mofetil and B cell-specific depletion
including the anti-CD20 monoclonal antibody rituximab.
Other immunological therapies currently in use in rheumatol-
ogy and neurology clinics may yet have application in NSAb-
mediated disease. Promising compounds are likely to be those
specifically targeting B cells and plasma cells and associated
antibody production, either directly or indirectly (e.g. toci-
lizumab, which targets the IL-6 receptor on B cells (Irani
and Vincent 2015)). Immunotherapies are associated with
a number of potentially serious side effects and should be
used with caution in the patients most likely to benefit.
Side effects include increased risk of infection (including
serious opportunistic infections of the CNS and systemi-
cally) with immunosuppressive treatments, fever, headache
and anaphylaxis with intravenous immunoglobulins and
cardiovascular instabili ty with plasma exchange.
Interestingly, steroid-induced psychosis is very rarely re-
ported in the treatment of autoimmune encephalopathies.
This may be because psychosis is often a presenting symp-
tom of the illness itself, and hence exacerbations are more
likely to go unnoticed or ascribed to illness progression or
potentially may be related to differential mechanisms un-
derlying behavioural disturbance in these individuals.
1616 Psychopharmacology (2016) 233:1605–1621
One example of the second, receptor-based approach has
been described in a therapeutic open-label case study by
Heresco-Levy and colleagues who gave D-serine to a female
with an NMDAR antibody-positive woman with a diagnosis
of chronic treatment-refractory schizophrenia. She also had
cortical and subcortical white matter MRI hyperintensities
and runs of ‘extreme delta brush’ on EEG (a pattern thought
to be pathognomonic of NMDAR antibody-mediated CNS
disease). Following treatment with D-serine, which is a
NMDAR co-agonist thought to enhance NMDAR function
by increasing the frequency of channel opening, the patient’s
EEG normalised and her psychosis improved (Heresco-Levy
et al. 2015).
Another future potential receptor-based approach, arising
from the work of Diamond and colleagues on NMDA NR2
antibodies in neuropsychiatric SLE, involves the synthesis
and systemic administration of a D-peptide which prevents
binding of antibody to its binding site without directly affect-
ing receptor function: in mice, these were well tolerated and
blocked the neurotoxic effects of NR2 NMDAR antibodies
(Huerta et al. 2006). Approaches using conformational epi-
topes would be required in autoimmune encephalopathies, as
the antibodies recognise non-linear native confirmations of the
target proteins. Other strategies aimed at blocking antibody-
antigen interaction are in development in neuromyelitis optica
and may also have application in NSAb-mediated disorders
(Papadopoulos et al. 2014).
Antibodies as therapeutic agents
Speculatively, and bearing inmind the growth of antibody-based
therapeutics in medicine generally, one could foresee how recent
work on NSAbs could facilitate the development of functionally
active antibodies to specific receptor targets as an emergent ther-
apeutic strategywithin neuropsychopharmacology. There is lim-
ited evidence that in some circumstances NSAbs could have a
protective function: Zerche and colleagues have demonstrated
that pre-existent NMDAR antibodies limit lesion size following
stroke in individuals with an intact BBB (Zerche et al. 2015).
Although themechanism is not known, it may be that NMDAR-
Ab-mediated receptor hypofunction limited glutamate-mediated
excitotoxicity in these individuals.
Conclusion
Increasingly, NSAbs are being reported in diverse clinical
populations with a range of psychiatric phenotypes. We have
presented convergent evidence that, outside of narrowly de-
fined psychiatric populations at the very least, NSAbs are
associated with a number of psychiatric syndromes, including
psychosis, tic and mood disorders, and evidence that
immunotherapy to treat the NSAbs is effective in treating
the psychiatric symptoms. However, several areas of contro-
versy remain, in particular whether the expanding numbers of
studies reporting increased prevalence of NSAbs in primary
psychiatric populations might require us to reconceptualize
the nature of a subset of these disorders. Studies dem-
onstrating whether NSAbs from psychiatric patients have
functional effects in vivo and in vitro are urgently required
to address this question, as are well-controlled trials of immu-
nological therapies in appropriately selected antibody-positive
patients.
NSAbs are potent effector molecules within the CNS that
can have profound effects on neuronal receptor function.
Their high affinity and remarkable specificities could offer
opportunities to study the biology of CNS-active molecules
in humans. A combined psychopharmacological and im-
munological approach to understanding their mechanisms of
action is necessary to understand both the neurobiological
basis of psychiatric symptoms as well as to develop new
treatment strategies that will arise from the inevitably
improved understanding of antibody-antigen interaction
within the CNS.
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